Section 9: Continuum of care: Summary and timeline

Slides:



Advertisements
Similar presentations
Summary Prepared by Melvyn Rubenfire, MD
Advertisements

Rationale and Design of the Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) at the University of California Los Angeles Gregg C. Fonarow,
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
Ischemic Heart Diseases IHD
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Stroke Awareness & Prevention Suheb Hasan, MD Health Seminar MCWS November 17, 2012.
METABOLIC SYNDROME Dr Gerhard Coetzer. Complaint Thirsty all the time Urinating more than usual Blurred vision Tiredness.
The Gap between Treatment Guidelines and Routine Care Treatment Patterns in the Management of High Risk Patients: Findings from the DETECT Study Hubert.
Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.
Rapid E clinical guidance in the management of Type 2 diabetes New Zealand Guidelines Group.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
Risk estimation and the prevention of cardiovascular disease SIGN 97.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
Routine Care Treatment of Type 2 Diabetes in Germany (DETECT Study) Tatjana Stojakovic 1, Hubert Scharnagl 1, Franz Freisinger 1, Andreas Tiran 1, David.
Blood pressure control in primary health care WORKSHOP
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
International Guidelines for Prevention of Atherosclerotic Cardiovascular Disease Prof. Mohamed Sobhy, MD, FACC Professor of Cardiology, Alex. University.
CRDAC Questions June 15, 2005 Antihypertensive drugs, with few exceptions, have no outcome claim in their labeling. This is inconsistent with their approval.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
New Guidelines for Myocardial Ischemia Management.
 2010 Cengage-Wadsworth Preventing Cardiovascular Disease Chapter 11.
4S: Scandinavian Simvastatin Survival Study
The IDEAL Cholesterol Christopher Cannon, M.D. TIMI Study Group Brigham and Women’s Hospital Cannon CP. JAMA 2005;294:
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
The Management of People at High Risk of CVD Dr Richard Healicon Mel Varvel NHS Improvement.
Copyleft Clinical Trial Results. You Must Redistribute Slides ASTEROID Trial A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived.
NICE –CG 181 Continuum of CVD Risk and its treatment
Title slide.
The American College of Cardiology Presented by Dr. Steven E. Nissen
Multi Modality Approach to Diagnosis of Ischemia in Post CABG Cases
AIM HIGH Niacin plus Statin to prevent vascular events
The Latest Lipid Guidelines:
Classification of total cholesterol levels
Diabetes Health Status Report
Post-Surgical Care for the Individual With PAD
FATS- Familial Atherosclerosis Treatment Study
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Lipids & Lipoproteins Part 2.
Treating Alcohol Abuse
Postintervention continuum of care: Focus on lipids
Section I: RAS manipulation C. Update on clinical trials in CAD
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Case 1: A 73-year-old white female with carotid disease
Section 5: Intervention and drug therapy
Type 2 diabetes: Overlap of clinical conditions
Section 7: Aggressive vs moderate approach to lipid lowering
This series of slides highlights a report based on a presentation at the Late-Breaking Trial Sessions of the 2005 American Heart Association Scientific.
Section III: Neurohormonal strategies in heart failure
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Non-Drug Ways to Promote Health by Lowering Cholesterol
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
LRC-CPPT and MRFIT Content Points:
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Goals & Guidelines A summary of international guidelines for CHD
LDL - How low can you go? Terry Jacobsen, MD
Major classes of drugs to reduce lipids
Cardiovascular Disease in Women Module IX: Presentation Resources and Internet Resources This slide set was updated April 2008.
Preventative Cardiology
Case 1: A 78-year-old white female with hypertension and hyperlipidemia Discussion Points: In that this patient has documented atherosclerotic vascular.
ATP III Guidelines Drug Therapy FUTURE RESEARCH.
Section 6: Update on lipid treatment guidelines
Cardiovascular Epidemiology and Epidemiological Modelling
Many post-MI patients are not receiving optimal therapy
Nutrition Interventions to Improve Quality of Care
Presentation transcript:

Section 9: Continuum of care: Summary and timeline Revascularization and lipid lowering Content Points: The AVERT study is consistent with other studies that show revascularization alone may not be sufficient to prevent ischemic events.37,53 In contrast, aggressive reduction of LDL-C appears to reduce CHD event rates and should be combined with appropriate revascularization.53

Revascularization and plaque pathology Content Points: As has been discussed, MI frequently evolves from mild-to-moderate obstructive plaques.31 It is not possible for interventionalists to treat all of these risky lesions. Indeed, they are frequently undetectable by angiography.

Continuum of care Content Points: In the context of the previous slide, therefore, a new paradigm of care is proposed that stresses a continuum of care involving both PCI and lipid-lowering therapy working in concert. PCI has a role in treating patients with significant symptoms, to whom it offers immediate benefits, including rapid improvement, improved angina tolerance at rest and during exercise and a reduced need for antianginal drugs. Lipid-lowering therapy is appropriate for all patients with CAD and is of long-term benefit. It treats plaque of all sizes and stages of development, reduces plaque progression and reduces CAD events.

ACT Content Points: This new paradigm can be summarized in the acronym ACT: – Awareness of opportunities to improve outcomes – Create synergies to achieve a continuum of care – Treat LDL-C aggressively

Clinical challenge: Aggressively  LDL-C to  CHD events Content Points: The slide summarizes the relationship between event rate and cholesterol lowering in primary and secondary prevention studies in the context of the NCEP target levels for patients with or without CHD.39 Event rates decreased with successively lower concentrations of LDL-C. The challenge is to help patients achieve their NCEP goal level.

Summary: Postintervention action plan Content Points: Based on current evidence, an appropriate lipid management strategy would include diet and exercise, with pharmacological therapy as indicated by the NCEP guidelines. Importantly, since we are dealing with patients with established atherosclerotic disease, the goal of reducing LDL-C to < 100 mg/dL must be achieved. An important step in reaching that goal will be to involve the patient in the management strategy. Make them aware of their lipid levels and their significance. In one study, 28% of patients with CAD did not know their cholesterol level.54 Patient education materials could also be useful aids to motivating patients and having them play an active role in their treatment.

Postintervention care timeline Content Points: The slide shows a sample critical care pathway that might be followed after PCI. As indicated, there are no currently accepted standards for determining the extent of atherosclerosis and assessing ischemia and a variety of approaches can be envisioned and debated. Prior to disharge, education and planning are essential: First, the patient needs to understand the effect of the PCI on the specific lesion and the future management of that lesion. Second, the patient needs to be aware of the developing atherosclerosis in the rest of the coronary tree and the medications and plans required to address the risk factors of this disease.

Postintervention care timeline Content Points: This slide extends the sample critical care pathway through 3 months following discharge. During this period, the interventional cardiologist can play an important role in establishing the scope of the management plan. There should be regular follow-up with patients, for the purpose of assessing the status of the dilated lesion(s), reinforcing the lipid and other goals, establishing clear expectations and encouraging good compliance. The ideal set of goals should include: – No angina and full activity – No evidence of ischemia on testing – Total cholesterol < 200 LDL < 100 (with LDL being the control parameter) HDL > 40 Triglycerides < 150 – BP < 130/50 –Control of diabetes, smoking cessation, exercise plan, weight reduction

Postintervention care timeline Content Points: The important role of the interventional cardiologist in establishing a continuum of care is highlighted in this final slide, which illustrates the long-term nature of the patient management plan. The specific goals should be personalized for each patient in a clear plan. The interventional cardiologist (and team) are in a key position to initiate, educate and send the appropriate signals to the patient, their family and the community physicians involved.